Member Exclusive

Epigenetics and Alzheimer’s: Phase I trials begin for epigenetic drug ORY-2001

First subject dosed in Phase I healthy volunteer study to evaluate Oryzon’s (Barcelona, Spain) oral epigenetic drug for the treatment of Alzheimer’s disease.

Go to the profile of Stella Bennett
Apr 07, 2016
0
0

Please sign in or register for FREE to view this content

Register to EpigenomicsNet – the epigenetics and epigenomics network

EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.

Register

0 Comments